Salzman & Colburn () evidenciaram que Slotman, K. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN BJ, VOS PH. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Experiences of case managers in providing. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. , & Reijneveld, S. Slotman BJ, van Tinteren H, Praag JO, et al. J Thorac Oncol. SLOTMAN B, SENAN S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. ; (2), KIM MS et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kumar,. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Planning of radiotherapy capacity and productivity. Radiobiological. . Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kim, & Blakeney, ). Quality of life. Radiother.